FIELD: immunotherapy.
SUBSTANCE: group of inventions relates to immunotherapy targeting FLT3. The following is disclosed: chimeric antigen receptors (CARs) that specifically bind to FLT3, polynucleotides encoding FLT3 CARs, engineered immune cells containing FLT3-specific CARs, methods of engineering immune cells to express FLT3-specific CARs, and methods of using T-cells with FLT3-specific CARs for the treatment of malignant neoplasms accompanied by impaired FLT3 expression.
EFFECT: obtaining chimeric antigene receptors targeting FLT3.
77 cl, 7 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| T-CELLS MODIFIED WITH CHIMERIC ANTIGEN RECEPTOR TARGETED TO CS1 FOR TREATMENT OF AMYLOIDOSIS AL | 2018 |
|
RU2774895C2 |
| CD20 THERAPY, CD22 THERAPY AND COMBINATION THERAPY WITH CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR (CAR) K CD19 | 2016 |
|
RU2752918C2 |
| T-CELLS MODIFIED WITH A CHIMERIC ANTIGEN RECEPTOR TARGETING CS1 | 2015 |
|
RU2727451C2 |
| CHIMERIC ANTIGEN RECEPTORS TARGETING HER2 | 2016 |
|
RU2753695C2 |
| CHIMERIC ANTIGEN RECEPTORS AIMED AT PSCA | 2016 |
|
RU2759879C2 |
| T-CELL RECEPTORS RECOGNIZING R175H OR Y220C MUTATION IN p53 | 2020 |
|
RU2830061C2 |
| CHIMERIC ANTIGEN RECEPTORS TARGETING CD70 | 2019 |
|
RU2801824C2 |
| C10orf54 ANTIBODIES AND USE THEREOF | 2015 |
|
RU2714232C2 |
| IMPROVED ANTI-FLT3 ANTIGEN-BINDING PROTEINS | 2019 |
|
RU2830982C2 |
| TREATMENT OF MALIGNANT NEOPLASM USING HUMANIZED CHIMERIC ANTIGEN RECEPTOR AGAINST BCMA | 2015 |
|
RU2751660C2 |
